Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

被引:23
|
作者
Sukhpreet Singh [1 ]
Natalia A Osna [1 ,2 ]
Kusum K Kharbanda [1 ,2 ,3 ]
机构
[1] Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System
[2] Department of Internal Medicine, Nebraska Medical Center
[3] Department of Biochemistry and Molecular Biology, Nebraska Medical Center
关键词
Alcoholic liver disease; Non-alcoholic fatty liver disease; Treatment options; Glucocorticoids; Liver transplantation;
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
Alcoholic liver disease(ALD)and non-alcoholic fatty liver disease(NAFLD)are serious health problems worldwide.These two diseases have similar pathological spectra,ranging from simple steatosis to hepatitis to cirrhosis and hepatocellular carcinoma.Although most people with excessive alcohol or calorie intake display abnormal fat accumulation in the liver(simple steatosis),a small percentage develops progressive liver disease.Despite extensive research on understanding the pathophysiology of both these diseases there are still no targeted therapies available.The treatment for ALD remains as it was 50 years ago:abstinence,nutritional support and corticosteroids(or pentoxifylline as an alternative if steroids are contraindicated).As for NAFLD,the treatment modality is mainly directed toward weight loss and co-morbidity management.Therefore,new pathophysiology directed therapies are urgently needed.However,the involvement of several inter-related pathways in the pathogenesis of these diseases suggests that a single therapeutic agent is unlikely to be an effective treatment strategy.Hence,a combination therapy towards multiple targets would eventually be required.In this review,we delineate the treatment options in ALD and NAFLD,including various new targeted therapies that are currently under investigation.We hope that soon we will be having an effective multi-therapeutic regimen for each disease.
引用
收藏
页码:6549 / 6570
页数:22
相关论文
共 50 条
  • [21] Current treatment of non-alcoholic fatty liver disease
    Ahmed, Mohamed H.
    Byrne, Christopher D.
    DIABETES OBESITY & METABOLISM, 2009, 11 (03): : 188 - 195
  • [22] Metformin in the treatment of non-alcoholic fatty liver disease
    De Lusong, M. A.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S192 - S192
  • [23] Current treatment of non-alcoholic fatty liver disease
    Paternostro, Rafael
    Trauner, Michael
    JOURNAL OF INTERNAL MEDICINE, 2022, 292 (02) : 190 - 204
  • [24] The diagnosis and treatment of non-alcoholic fatty liver disease
    Altinbas, A.
    Sowa, J. -P.
    Hasenberg, T.
    Canbay, A.
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2015, 61 (03) : 159 - 169
  • [25] Treatment regimens for non-alcoholic fatty liver disease
    Lam, Brian P.
    Younossi, Zobair M.
    ANNALS OF HEPATOLOGY, 2009, 8 : S51 - S59
  • [26] Rosiglitazone treatment in non-alcoholic fatty liver disease
    Szymanska-Garbacz, E.
    Saryusz-Wolska, M.
    Jablkowski, M.
    Bialkowska, J.
    Borkowska, A.
    Omulecka, A.
    Loba, J.
    Czupryniak, L.
    DIABETOLOGIA, 2008, 51 : S368 - S368
  • [27] Current treatment for non-alcoholic fatty liver disease
    Moctezuma-Velazquez, C.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2018, 83 (02): : 125 - 133
  • [28] Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
    Sven Francque
    Luisa Vonghia
    Advances in Therapy, 2019, 36 : 1052 - 1074
  • [29] Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Dowman, J. K.
    Tomlinson, J. W.
    Newsome, P. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (05) : 525 - 540
  • [30] Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review
    Mohammadi, Zahra
    Poustchi, Hossein
    Motamed-Gorji, Nazgol
    Eghtesad, Sareh
    Hekmatdoost, Azita
    Saniee, Parastoo
    Merat, Shahin
    ARCHIVES OF IRANIAN MEDICINE, 2020, 23 (01) : 44 - 52